A Phase I, Two Part Study Exploring the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effect of Ascending Doses of BL-8040 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 23 Aug 2017
Price : $35 *
At a glance
- Drugs Motixafortide (Primary)
- Indications Stem cell mobilisation
- Focus Adverse reactions
- Sponsors BioLineRx
- 23 Aug 2017 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 19 Apr 2016 Results published in BioLineRx media release.
- 30 Jul 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.